Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Long-Term Debt Repayments (2022 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $11.9 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Debt Repayments changed N/A year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Mar 2024, down 18.71%, and an annual FY2023 reading of $18.1 million, up 117.27% over the prior year.
  • Long-Term Debt Repayments was $11.9 million for Q2 2023 at Alaunos Therapeutics, up from $6.2 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $11.9 million in Q2 2023 and bottomed at $2.1 million in Q3 2022.